Original Article

The Indian Journal of Pediatrics

, Volume 79, Issue 4, pp 478-482

First online:

Efficacy and Safety of Saccharomyces boulardii in Acute Childhood Diarrhea: A Double Blind Randomised Controlled Trial

  • Musheer RiazAffiliated withDepartment of Pediatrics, Jawaharlal Nehru Medical College, AMU
  • , Seema AlamAffiliated withDepartment of Pediatric Hepatology, Institute of Liver and Biliary Sciences Email author 
  • , Abida MalikAffiliated withDepartment of Microbiology, Jawaharlal Nehru Medical College, AMU
  • , S. Manazir AliAffiliated withDepartment of Pediatrics, Jawaharlal Nehru Medical College, AMU

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access



To see the efficacy and safety of 250 mg of Saccharomyces boulardii twice daily for 5 d in acute childhood diarrhea.


Children aged between 3 mo and 59 mo with acute onset diarrhea (of less than 48 h) admitted in DTTU (diarrhea treatment and training unit) were included and those with clinical evidence of severe malnutrition, systemic infection, encephalopathy and/or convulsion, electrolyte imbalance, invasive diarrhea or previous use of any probiotics were excluded from the study. Those included randomly were given either a placebo or Saccharomyces boullardi (SB) in identical packets mixed with puffed rice powder.


Mean post intervention duration of diarrhea was significantly (95% CI = −28.13 to −5.43) shorter in SB group (52.08 ± 24.57 h) as compared to placebo group (64.04 ± 30.43 h). The time of appearance of first semi formed stool in SB group (39.48 ± 23.09 h) was significantly (95% CI −25.4 to −3.87) shorter than the placebo group (54.13 ± 28.21 h). No statistically significant difference was found in rest of the parameters.


There is initial evidence available that SB may have a therapeutic role in the management of acute childhood diarrhea.


Acute diarrhea Probiotics Saccharomyces boularrdii Therapeutic role